Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.

Chase TN, Farlow MR, Clarence-Smith K.

Neurotherapeutics. 2017 Apr;14(2):405-416. doi: 10.1007/s13311-016-0511-x.

2.

Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Chase TN.

Neurotox Res. 2011 Feb;19(2):266-78. doi: 10.1007/s12640-010-9196-9. Epub 2010 May 15. Review.

PMID:
20473601
3.

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD.

Pharmacol Biochem Behav. 2008 Oct;90(4):540-4. doi: 10.1016/j.pbb.2008.04.010.

4.

Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum.

Liang ZQ, Wang X, Li LY, Wang Y, Chen RW, Chuang DM, Chase TN, Qin ZH.

J Neurosci Res. 2007 May 1;85(6):1295-309.

PMID:
17385714
5.

NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.

Liang ZQ, Li YL, Zhao XL, Han R, Wang XX, Wang Y, Chase TN, Bennett MC, Qin ZH.

Brain Res. 2007 May 11;1145:190-203. Epub 2007 Feb 7.

PMID:
17368433
6.

Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.

Smith CP, Oh JD, Bibbiani F, Collins MA, Avila I, Chase TN.

Neuropharmacology. 2007 Feb;52(2):515-26. Epub 2006 Nov 20.

PMID:
17116309
7.

Glutamate release inhibition ineffective in levodopa-induced motor complications.

Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN.

Mov Disord. 2006 Sep;21(9):1380-3.

PMID:
16758479
8.

Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain.

Andringa G, Bol JG, Wang X, Boekel A, Bennett MC, Chase TN, Drukarch B.

Neuropathol Appl Neurobiol. 2006 Apr;32(2):157-69.

PMID:
16599944
9.

Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.

Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN.

Exp Neurol. 2005 Dec;196(2):422-9. Epub 2005 Oct 3.

PMID:
16203001
10.

Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.

Liang ZQ, Wang XX, Wang Y, Chuang DM, DiFiglia M, Chase TN, Qin ZH.

Neurobiol Dis. 2005 Nov;20(2):562-73.

PMID:
15922606
11.

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN.

Mov Disord. 2005 Aug;20(8):932-6.

PMID:
15791634
12.

Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia.

Zhang HL, Huang ZH, Zhu Y, Liang ZQ, Han R, Wang XX, Chase TN, Qin ZH.

Brain Res. 2005 Mar 28;1039(1-2):203-6.

PMID:
15781063
13.

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.

Bibbiani F, Costantini LC, Patel R, Chase TN.

Exp Neurol. 2005 Mar;192(1):73-8.

PMID:
15698620
14.

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN.

Mov Disord. 2004 Oct;19(10):1183-6.

PMID:
15390018
15.

NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.

Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD.

Neuropharmacology. 2004 Aug;47(2):184-94.

PMID:
15223297
16.

Striatal plasticity and extrapyramidal motor dysfunction.

Chase TN.

Parkinsonism Relat Disord. 2004 Jul;10(5):305-13. Review.

PMID:
15196510
17.

Comment on "Contributions of anthropogenic and natural forcing to recent tropopause height changes".

Pielke RA Sr, Chase TN.

Science. 2004 Mar 19;303(5665):1771; author reply 1771. No abstract available.

18.

Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.

Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC.

FASEB J. 2004 May;18(7):932-4. Epub 2004 Mar 4.

PMID:
15001552
19.

Translating A2A antagonist KW6002 from animal models to parkinsonian patients.

Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD.

Neurology. 2003 Dec 9;61(11 Suppl 6):S107-11. Review.

PMID:
14663022
20.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.

Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA, Chase TN; KW-6002 US-001 Study Group.

Neurology. 2003 Dec 9;61(11 Suppl 6):S97-100. Review.

PMID:
14663020
21.

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.

Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN.

Exp Neurol. 2003 Nov;184(1):285-94.

PMID:
14637099
23.

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.

Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN.

Neurology. 2003 Aug 12;61(3):293-6.

PMID:
12913186
24.

Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Chase TN, Bibbiani F, Oh JD.

Neurotox Res. 2003;5(1-2):139-46. Review.

PMID:
12832228
25.

Complications of a trophic xenotransplant approach in parkinsonian monkeys.

Blanchet PJ, Konitsiotis S, Mochizuki H, Pluta R, Emerich DF, Chase TN, Mouradian MM.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):607-12.

PMID:
12787846
28.

The influence of land-use change and landscape dynamics on the climate system: relevance to climate-change policy beyond the radiative effect of greenhouse gases.

Pielke RA Sr, Marland G, Betts RA, Chase TN, Eastman JL, Niles JO, Niyogi DD, Running SW.

Philos Trans A Math Phys Eng Sci. 2002 Aug 15;360(1797):1705-19.

PMID:
12460493
29.

Renaissance of amantadine in the treatment of Parkinson's disease.

Blanchet PJ, Metman LV, Chase TN.

Adv Neurol. 2003;91:251-7. Review. No abstract available.

PMID:
12442683
30.

Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells.

Wang X, Qin ZH, Leng Y, Wang Y, Jin X, Chase TN, Bennett MC.

J Neurochem. 2002 Dec;83(5):1094-102.

31.

Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.

Oh JD, Bibbiani F, Chase TN.

Exp Neurol. 2002 Oct;177(2):557-64.

PMID:
12429201
32.

Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.

Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, Weinberger DR, Mattay VS.

J Neurosci. 2002 Oct 15;22(20):9099-103. Erratum in: J Neurosci. 2002 Dec 15;22(24):1a..

33.
34.

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.

Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN.

Neurology. 2002 Sep 10;59(5):694-9.

PMID:
12221159
35.

The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates.

Jeffries KJ, Schooler C, Schoenbach C, Herscovitch P, Chase TN, Braun AR.

Neuropsychopharmacology. 2002 Jul;27(1):92-104.

36.

Dopaminergic modulation of cortical function in patients with Parkinson's disease.

Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR.

Ann Neurol. 2002 Feb;51(2):156-64.

PMID:
11835371
37.

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.

Bibbiani F, Oh JD, Chase TN.

Neurology. 2001 Nov 27;57(10):1829-34.

PMID:
11723272
38.

Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.

Chase TN, Konitsiotis S, Oh JD.

Adv Neurol. 2001;86:355-60. Review. No abstract available.

PMID:
11553996
39.

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U.

Mov Disord. 2001 May;16(3):515-20.

PMID:
11391748
40.

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL.

Mov Disord. 2001 May;16(3):459-63.

PMID:
11391739
41.

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN.

Clin Neuropharmacol. 2001 May-Jun;24(3):163-9.

PMID:
11391128
42.
43.

Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum.

Qin ZH, Wang Y, Chen RW, Wang X, Ren M, Chuang DM, Chase TN.

J Pharmacol Exp Ther. 2001 Apr;297(1):78-87.

PMID:
11259530
44.

Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.

Chase TN, Oh JD.

Trends Neurosci. 2000 Oct;23(10 Suppl):S86-91. Review.

PMID:
11052225
45.

Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.

Chase TN, Oh JD, Konitsiotis S.

J Neurol. 2000 Apr;247 Suppl 2:II36-42. Review.

PMID:
10991664
46.

Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.

Marin C, Jimenez A, Bonastre M, Chase TN, Tolosa E.

Synapse. 2000 Jun 15;36(4):267-74.

PMID:
10819904
47.

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.

Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN.

Neurology. 2000 Apr 25;54(8):1589-95.

PMID:
10762498
48.

Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.

Chase TN, Oh JD.

Ann Neurol. 2000 Apr;47(4 Suppl 1):S122-9; discussion S129-30. Review.

PMID:
10762139
50.

Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation.

Nakai M, Qin ZH, Chen JF, Wang Y, Chase TN.

J Neurochem. 2000 Feb;74(2):647-58.

Supplemental Content

Loading ...
Support Center